齐拉西酮联合艾司西酞普兰治疗难治性抑郁症的效果观察

目的 探讨齐拉西酮联合艾司西酞普兰治疗难治性抑郁症（TRD）的效果与安全性。方法 将60例TRD患者随机分为研究组（齐拉西酮联合艾司西酞普兰）和对照组（单用艾司西酞普兰），每组各30例，疗程8周。治疗前及治疗后第2、4、6、8周分别采用汉密尔顿抑郁量表（HAMD）、不良反应量表（TESS）评定疗效和不良反应。结果 研究组总有效率为70．0％，对照组总有效率为43．3％，差异有统计学意义（χ^2=4．34，P〈0．05）。治疗2周末研究组HAMD评分较对照组明显下降，差异有统计学意义（P〈0．05）。治疗8周后，两组间HAMD比较差异有统计学意义（P〈0．01），两组间TESS评分差异无统计学意义（P〉0．05）。结论 齐拉西酮联合艾司西酞普兰治疗TRD的效果较佳，安全性高。

Effect observation of escitalopram combination with ziprasidone in the treatment of treatment-resistant depression

Objective To compare the curative effect and safety of ziprasidone and esicitalopram in the treatment of treatment-resistant depression. Methods 60 patients with treatment-resistant depression were divided into study group （escitalopram combination with ziprasidone） and control group （alone esicitalopram）,eaeh group of 30 cases,the course of 8 weeks.Hamilton depressive scale （HAMD） and treatment emergent symptom scale （TESS） were used to evaluate the efficacy and adverse reactions before and after treatment 2,4,6,8 weeks. Results The total effective rates of study group and control group were 70.0% and 43.3% respectively,there was significant difference between two groups （χ^2=4.34,P〈 0.05）.The HAMD scores in study group was significantly lower than that of the control group after 2 weeks.After 8 weeks,the HAMD in the two groups,the difference was statistically significant （P〈0.01）,the TESS scores in the two groups,there was no statistically significant difference （P〉0.05）. Conclusion Ziprasidone combined with esicitalopram in the treatment of treatment-resistant depression has better efficacy and high safety.